Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort.

IF 7.1 1区 医学 Q1 HEMATOLOGY Blood advances Pub Date : 2025-05-13 DOI:10.1182/bloodadvances.2024014632
Mareike Tometten, Fabian Beier, Martin Kirschner, Yannic Schumacher, Jeanette Walter, Margherita Vieri, Kim Kricheldorf, Alexander Röth, Uwe Platzbecker, Markus Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Höchsmann, Stefan Balabanov, Claas Hinze, Jörg Chromik, Michael Heuser, Michael Kreuter, Marcin W Wlodarski, Miriam Elbracht, Ingo Kurth, Steffen Koschmieder, Jens Panse, Susanne Isfort, Robert Meyer, Tim H Brümmendorf
{"title":"Late-onset telomere biology disorders in adults: clinical insights and treatment outcomes from a retrospective registry cohort.","authors":"Mareike Tometten, Fabian Beier, Martin Kirschner, Yannic Schumacher, Jeanette Walter, Margherita Vieri, Kim Kricheldorf, Alexander Röth, Uwe Platzbecker, Markus Radsak, Philippe Schafhausen, Selim Corbacioglu, Britta Höchsmann, Stefan Balabanov, Claas Hinze, Jörg Chromik, Michael Heuser, Michael Kreuter, Marcin W Wlodarski, Miriam Elbracht, Ingo Kurth, Steffen Koschmieder, Jens Panse, Susanne Isfort, Robert Meyer, Tim H Brümmendorf","doi":"10.1182/bloodadvances.2024014632","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Pathogenic germ line variants affecting proper telomere maintenance result in premature telomere shortening and cause telomere biology disorders (TBDs). Although classical dyskeratosis congenita in children is rather well defined, late-onset (\"cryptic\") TBDs remain underrecognized, resulting in underdiagnosis and inadequate treatment in affected adults. Here, we present a series of adult TBD cases collected through the German TBD reference center between 2014 and 2024. Patients aged ≥18 years with an age-matched telomere length (TL) <10th percentile in lymphocytes, a detection of either a variant of uncertain significance, a pathogenic, or a likely pathogenic variant in TBD-associated genes, and available clinical data were included in this analysis. Based on this, a novel point-based algorithm for categorization into proven, probable, and suspected-only TBD cases was developed. Of 1537 TL analyses, 42 patients with proven (n = 29) or probable (n = 13) TBD were identified. The median age at first clinical manifestation and at diagnosis was 20.0 and 34.1 years, respectively. Bone marrow failure (BMF) was the most frequent manifestation observed in our cohort (73.8%), followed by liver or interstitial lung diseases (50.0% and 41.5%, respectively). Immunosuppressive therapy was administered in 6 patients with BMF, but none of them responded. In comparison, 8 of 8 evaluable patients treated with androgen derivatives showed hematologic response. Our data provide novel real-world insights into the clinical manifestation spectrum, diagnosis, clinical course, and treatment of TBD in adult, late-onset cases of this hereditary disease.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"2183-2191"},"PeriodicalIF":7.1000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12243046/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024014632","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Pathogenic germ line variants affecting proper telomere maintenance result in premature telomere shortening and cause telomere biology disorders (TBDs). Although classical dyskeratosis congenita in children is rather well defined, late-onset ("cryptic") TBDs remain underrecognized, resulting in underdiagnosis and inadequate treatment in affected adults. Here, we present a series of adult TBD cases collected through the German TBD reference center between 2014 and 2024. Patients aged ≥18 years with an age-matched telomere length (TL) <10th percentile in lymphocytes, a detection of either a variant of uncertain significance, a pathogenic, or a likely pathogenic variant in TBD-associated genes, and available clinical data were included in this analysis. Based on this, a novel point-based algorithm for categorization into proven, probable, and suspected-only TBD cases was developed. Of 1537 TL analyses, 42 patients with proven (n = 29) or probable (n = 13) TBD were identified. The median age at first clinical manifestation and at diagnosis was 20.0 and 34.1 years, respectively. Bone marrow failure (BMF) was the most frequent manifestation observed in our cohort (73.8%), followed by liver or interstitial lung diseases (50.0% and 41.5%, respectively). Immunosuppressive therapy was administered in 6 patients with BMF, but none of them responded. In comparison, 8 of 8 evaluable patients treated with androgen derivatives showed hematologic response. Our data provide novel real-world insights into the clinical manifestation spectrum, diagnosis, clinical course, and treatment of TBD in adult, late-onset cases of this hereditary disease.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
迟发性端粒生物学疾病:回顾性登记队列的临床观察和治疗结果。
影响端粒正常维持的致病性种系变异导致端粒过早缩短并引起端粒生物学紊乱(tbd)。虽然儿童典型先天性角化不良症的定义相当明确,但迟发性(“隐性”)tbd仍未得到充分认识,导致受影响成人的诊断和治疗不足。在这里,我们展示了2014年至2024年间通过德国TBD参考中心收集的一系列成人TBD病例。年龄≥18岁,淋巴细胞年龄匹配端粒长度(TL) < 10百分位数,检测到不确定意义的变异,tbd相关基因的致病性或可能致病性变异,以及现有的临床数据被纳入本分析。在此基础上,提出了一种新的基于点的分类算法,分别将TBD分类为已证实、可能和疑似病例。在总共1537例TL分析中,鉴定出42例确诊(n=29)或可能(n=13) TBD患者。首次临床表现和诊断的中位年龄分别为20.0岁和34.1岁。骨髓衰竭(BMF)是我们队列中最常见的表现(73.8%),其次是肝脏或肺间质性疾病(分别为50.0%和41.5%)。对6例BMF患者进行免疫抑制治疗,均无应答。相比之下,8名接受雄激素衍生物治疗的可评估患者中有8名出现血液学反应。我们的数据为成人迟发性TBD的临床表现谱、诊断以及临床病程和治疗提供了新的现实见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood advances
Blood advances Medicine-Hematology
CiteScore
12.70
自引率
2.70%
发文量
840
期刊介绍: Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
期刊最新文献
Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden. Small-molecule inhibition of γ-glutamyl carboxylase reveals a novel anticoagulant strategy. Epo and hypoxia accelerate a pattern of gradual cell cycle shortening in BFU-e and CFU-e erythroid progenitors in vivo. Rapid detection of fibrinolytic activation in postpartum hemorrhage and acute obstetric coagulopathy using a novel assay. MPN-FIT: a randomized controlled pilot trial of supervised exercise in myeloproliferative neoplasms.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1